At MBX, we are reimagining how patients live with endocrine diseases.
Enabled by our proprietary PEPTM platform technology, we have a growing pipeline of therapeutic candidates in various stages of clinical development.
“Our pipeline of PEP candidates includes clinically validated targets with well-defined regulatory pathways to address significant unmet medical needs. Our efforts will make a meaningful impact in improving the lives of individuals with endocrine disorders.”
From Pipeline to Promise
World-Class Peptide Platform
Explore what patients have to say and learn more about current clinical trials and how MBX Biosciences is striving to make a difference for people living with hypoparathyroidism and post-bariatric hypoglycemia.Patients